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Gentamicin C complex from Micromonospora echinospora re-
mains a globally important antibiotic, and there is revived in-
terest in the semisynthesis of analogs that might show improved
therapeutic properties. The complex consists of five compo-
nents differing in their methylation pattern at one or more sites
in the molecule. We show here, using specific gene deletion and
chemical complementation, that the gentamicin pathway up to
the branch point is defined by the selectivity of the methyl-
transferases GenN, GenD1, and GenK. Unexpectedly, they com-
prise a methylation network in which early intermediates are
ectopically modified. Using whole-genome sequence, we have
also discovered the terminal 6′-N-methyltransfer required to
produce gentamicin C2b from C1a or gentamicin C1 from C2,
an example of an essential biosynthetic enzyme being located
not in the biosynthetic gene cluster but far removed on the
chromosome. These findings fully account for the methylation
pattern in gentamicins and open the way to production of in-
dividual gentamicins by fermentation, as starting materials for
semisynthesis.
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Gentamicins are clinically valuable aminoglycoside antibioticsisolated as gentamicin C complex, a mixture of five components
(Fig. 1), from the filamentous bacterium Micromonospora echino-
spora. Gentamicins are protein synthesis inhibitors used to combat
Gram-negative bacterial infections. They are also being actively
explored for use in other applications (1–3). However, genta-
micins carry a serious risk of kidney damage and irreversible
hearing loss (4, 5), which limits their utility. Encouragingly, indi-
vidual components of the gentamicin mixture may have lower
toxicity (6, 7). Individual components of gentamicin C can
already be separated after manual chemical derivatization (8),
but achieving this by low-cost direct fermentation would sig-
nificantly advance interest in single components both as starting
material for semisynthesis to novel gentamicins and for testing as
therapeutics in their own right.
Gentamicins are modified sugars containing an unusual
aminocyclitol ring (2-deoxystreptamine, 2-DOS) (9, 10). The
enzymatic steps that lead to the 2-DOS scaffold, and thence to
the pseudodisaccharide paromamine (11–13) and the pseu-
dotrisaccharide gentamicin A2 (1) (14) (Fig. 1), have all been
elucidated, and more recently rapid progress has also been
made in delineating the later steps of gentamicin biosynthesis,
greatly aided by the sequencing of the gentamicin biosyn-
thetic gene cluster (15–17) and the related sisomicin cluster
(18). We have previously used a combination of genetic and
biochemical evidence to reveal that, starting from the inter-
mediate 3″-dehydro-3″-oxo-gentamicin A2 (DAA2) (2) (Fig. 1),
the S-adenosylmethionine (SAM)-dependent methyltransferase
GenN catalyzes 3′′-N-methylation, followed by 4″-C-methylation
catalyzed by a cobalamin- and radical SAM-dependent methyl-
transferase GenD1, to form gentamicin X2 (4) (19). In the same
way, we (20) and others (21–24) have shown that a second
cobalamin- and radical SAM-dependent methyltransferase,
GenK, catalyzes 6′-C-methylation of gentamicin X2 (4) to
initiate the branch of the gentamicin pathway that leads via
G418 (5) to gentamicin components C2a, C2, and C1. The
full mechanistic details of the subsequent transamination and
dehydroxylation steps remain to be clarified, although the de-
hydrogenase GenQ (20), phosphotransferase GenP, and the
pyridoxal-dependent enzymes GenB1, GenB2, GenB3, and
GenB4 have all been implicated in this enigmatic process (20, 25,
26). Finally, the terminal step in both branches of the pathway
involves the (partial) conversion of C1a into C2b and of C2
into C1, catalyzed by an unidentified 6′-N-methyltransferase
(or possibly two different methyltransferases). Given the de-
cisive role of methylation in shaping the pathway to the gen-
tamicin C complex, we have used mutant strains ofM. echinospora
engineered to contain different complements of GenN, GenD1,
and GenK to investigate the substrate selectivity of these
known methyltransferases to determine the scope for altering
the methylation pattern; and we have tracked down and iden-
tified, by combined biochemical and genetic approaches, the
terminal methyltransferase (named GenL). GenL is located
on its own 2.54 Mbp from the previously characterized genta-
micin gene cluster. We show that GenL is necessary and suf-
ficient to catalyze the 6′-N-methylation of both C2 and C1a.
It follows that future judicious manipulation of the levels of
(in particular) GenK and GenL activity in cells should permit
targeted enrichment of individual components of the genta-
micin C complex.
Significance
Aminoglycosides remain a vital clinical asset. Gentamicin C
complex in particular is remarkably potent in treating sys-
temic Gram-negative infections, and semisynthetic genta-
micins that combat pathogen resistance or show reduced
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clustered genes and enzymes that define a methylation
network in gentamicin biosynthesis and also identify a re-
mote gene on the chromosome encoding the essential
methyltransferase GenL, which is decisive for the propor-
tions of the five major components present in the gentamicin
C complex. This is an important step toward engineered
fermentation to produce single components as valuable
starting materials for semisynthesis of next-generation
aminoglycoside antibiotics.
Author contributions: F.H., P.F.L., and Y.S. designed research; S.L., J.G., A.R., F.H., B.X.,
Y.L., and Y.S. performed research; S.L., J.G., A.R., F.H., B.X., Y.L., Z.D., P.F.L., and Y.S.
analyzed data; and F.H., P.F.L., and Y.S. wrote the paper.
The authors declare no conflict of interest.
This article is a PNAS Direct Submission.
This open access article is distributed under Creative Commons Attribution-NonCommercial-
NoDerivatives License 4.0 (CC BY-NC-ND).
Data deposition: The sequences reported in this paper have been deposited in the Gen-
Bank database (accession nos. KY971520 and MF036116–MF036138).
1S.L. and J.G. contributed equally to this work.
2To whom correspondence may be addressed. Email: yhsun@whu.edu.cn or pfl10@cam.
ac.uk.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1711603115/-/DCSupplemental.
1340–1345 | PNAS | February 6, 2018 | vol. 115 | no. 6 www.pnas.org/cgi/doi/10.1073/pnas.1711603115
Results
Systematic Deletion of One or More of the Methyltransferase Genes
genN, genD1, and genK Reveals Alternative Minor Pathways for
Methylation. Commercial samples of gentamicin C complex obtained
by fermentation contain variable amounts of minor gentamicin me-
tabolites as impurities. Careful analysis has detected as many as 21
such minor products in a single sample (27). For 6 of these, the
structure could be determined by MS and MSn methods, and struc-
tures could also be proposed for 13 others (27). In previous work it
has been shown that levels of certain metabolites with altered
methylation patterns are enhanced upon deletion of either genN
(19, 28) or genK (20). We therefore set out systematically to alter
the complement of known methyltransferase genes and to study
the metabolites produced.
First, the single mutants of genN and genD1, which were
constructed in our previous studies (19, 20), were used to gen-
erate the series of mutants ΔgenD1ΔgenN, ΔgenD1ΔgenK,
ΔgenNΔgenK, and ΔgenD1ΔgenKΔgenN. In these mutants, an
internal fragment has been deleted in-frame, respectively, from
genN, genD1, and genK. These mutants were confirmed by PCR
and Southern blotting and then fermented (SI Appendix, Fig. S1
A–D). The extracts were analyzed by using liquid chromatogra-
phy coupled with electrospray ionization high-resolution mass
spectrometry (LC-ESI-HRMS) and tandem mass spectrometry
(MS/MS).
Fig. 1. Methyltransfer reactions in gentamicin biosynthetic pathway. The determined major and minor alternative pathways in the methylation network are
indicated by boldface type and solid arrows, respectively. The dashed arrows refer to conversions without substantial experimental support. Methyl-
transferases and their roles revealed in this study of GenN, GenD1, GenK, and GenL are highlighted in magenta, orange, blue, and red, respectively. The
extents of methylation are shown in the dashed rectangle boxes. Carbon numbering is shown with the structure of 1.
Li et al. PNAS | February 6, 2018 | vol. 115 | no. 6 | 1341
M
IC
RO
BI
O
LO
G
Y
The triple-mutant ΔgenD1ΔgenKΔgenN produced small
amounts of 2 (Fig. 1 and SI Appendix, Figs. S2A and S3A) (19),
the upstream precursor of gentamicin A (3) (Figs. 1 and 2A and
SI Appendix, Fig. S2B). NMR data confirmed the structure of 2
as a nonmethylated species as previously proposed (SI Appendix,
Fig. S3A and Table S1). The intermediate 1 (Figs. 1 and 2A) was
present as the major species, but no other gentamicin-related
metabolite was present. The ΔgenD1ΔgenK mutant produced
1 and 3 (Figs. 1 and 2B), but no other methylated intermediates
or other gentamicins. These results confirm that GenN is essential
for the methylation on 3′′-N of 2. In extracts of the ΔgenNΔgenK
mutant, intermediates 1 and 2 were detected at levels similar to
those in the triple mutant, but an additional compound with
the same molecular mass as 3 was observed, singly methylated on
3′′-N (Figs. 1 and 2C). Given the known regiospecificity of GenD1
(19), the site of modification is proposed to be at C-4′′ (SI Ap-
pendix, Fig. S2C). This metabolite, named here gentamicin A-1 (6)
(Fig. 1 and SI Appendix, Fig. S2C), has been described as a trace
component of a wild-type fermentation (27). In the extract of the
ΔgenD1ΔgenN mutant, 2 was detected at levels similar to those in
the triple mutant along with two 6′-C-methylated metabolites (Fig.
2D). One of these is formed as a result of the precocious action of
GenK on 2 and is named here gentamicin A-2 (7) (Figs. 1 and 2D
and SI Appendix, Figs. S2D and S3B and Table S1). It is assumed
to have the same relative configuration at C-6′ as 5 (Fig. 1 and SI
Appendix, Fig. S2E) and has also been previously described as a
trace component of a wild-type fermentation (26). The second
metabolite A2e (8) (Figs. 1 and 2D and SI Appendix, Fig. S2F) is
formed by the known precocious action of GenK on 1 (19, 24).
We repeated our previous analysis of the ΔgenN, ΔgenD1 and
ΔgenK mutants (19, 20) and scrutinized the extracts carefully for
metabolites with an altered methylation pattern. The ΔgenK
mutant produced 3 and 4 (SI Appendix, Fig. S2G) as expected
but only a trace of the metabolite we have assigned as 6 (Figs. 1
and 2E), confirming that GenD1 fails to compete successfully
with GenN for methylation of 2. The ΔgenD1 mutant in contrast
produced a relatively large amount of the known doubly meth-
ylated metabolite gentamicin Ae (9) (Figs. 1 and 2F and SI
Appendix, Fig. S2H) (19, 27), again a consequence of the
precocious action of GenK. We confirmed the structure of 9
by NMR (SI Appendix, Fig. S3C and Table S1). The ΔgenN
mutant produced low levels of 2, but mainly produced 1, as
well as the singly methylated species 6, 7, 8, and an in-
termediate with the same molecular mass and MS/MS frag-
mentation as 9, which we name here gentamicin X2-1 (10)
(Figs. 1 and 2G and SI Appendix, Fig. S2I). This compound,
which has also been described as a trace component of wild-
type gentamicin fermentation (27), is most likely methylated
at both C-4″ and C-6′ positions. Another compound with the
same molecular mass and MS/MS fragmentation as 10 was
also observed, named here X2-1-i, which may be an isomer of
it (Fig. 2G and SI Appendix, Fig. S2I). These species with
various methylation patterns suggest a metabolic network in
the pathway, in which methylations at the three sites occur rela-
tively independently of each other rather than in a strictly
fixed order.
Bioconversion in Vivo and in Vitro of Gentamicin Metabolites Confirms
the Selectivity of Methylation by GenN, GenD1, and GenK. Established
gentamicin intermediates 2, 3, and 4 as well as gentamicin me-
tabolites with altered methylation patterns 6, 7, 9, and 10 were
isolated from the mutants described above, as described in Ma-
terials and Methods (SI Appendix). We aimed to interrogate di-
rectly the ability of individual methyltransferases to use these
compounds as substrates and verify which of the possible con-
versions in the methylation network actually occur. To do this, the
gentamicin biosynthetic gene cluster (GenBank accession no.
KY971520) from grmB to genN was knocked out by deletion of
a 40,524-bp fragment to generate the ΔBN mutant, which was
confirmed by PCR and Southern blotting analysis (SI Appendix,
Fig. S1E). Complementation of the ΔBN mutant by using plasmid
pWHU91 (SI Appendix, Table S2) containing genN and gmrA
under the control of the PermE* promoter, respectively, gen-
erated ΔBN::gmrA+genN (SI Appendix, Fig. S5B and Table S3).
In parallel, ΔBN::gmrA+genD1 and ΔBN::gmrA+genK were
constructed in the same way with pWHU92 and pWHU93 (SI
Appendix, Figs. S5 C and D, and Table S3). The gene gmrA that
confers gentamicin self-resistance was present to avoid toxicity of
gentamicin metabolites in the host strain. The strain ΔBN::gmrA
was constructed as a negative control by using pWHU90 (SI
Appendix, Table S2), which contains gmrA only, under the control of
the constitutive PermE* promoter (SI Appendix, Fig. S5A).
The results from LC-ESI-HRMS and MS/MS showed that
feeding either 2, 3 (the normal substrate), 7, or 9 to ΔBN::
gmrA+genD1 led to detectable methylation, which is presumed
to be at C-4″ (Fig. 3A). Likewise, feeding 2, 3, or 4 (the normal
substrate) to ΔBN::gmrA+genK in each case led to detectable
methylation (presumed to be at C-6′) (Fig. 3B). In contrast,
feeding of 6 to this strain did not produce 10. Meanwhile,
feeding of 2 (the normal substrate) to ΔBN::gmrA+genN
generated 3, and feeding of 7 to this strain generated 9 (Fig.
3C). However, neither 6 nor 10 were methylated in this strain.
Consistent with the in vivo biotransformation results, purified
His-tagged recombinant GenN catalyzed methylation of 2 and 7
into 3 and 9, respectively, with SAM as a methyl donor (Fig. 4).
No methylated product was observed when 6 and 10 were used as
substrates under the same assay conditions.
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Fig. 2. LC-ESI-HRMS analysis of gentamicin-related intermediates from
mutant strains. Extracted ion chromatogram of intermediates in (A)
ΔgenD1ΔgenKΔgenN, (B) ΔgenD1ΔgenK, (C)ΔgenNΔgenK, (D) ΔgenD1ΔgenN,
(E) ΔgenK, (F) ΔgenD1, and (G) ΔgenN.
1342 | www.pnas.org/cgi/doi/10.1073/pnas.1711603115 Li et al.
The Enzyme GenL, Required for the Terminal 6′-N-Methylation Step in
Both Branches of the Gentamicin Biosynthetic Pathway, Has Been
Identified. Preliminary experiments showed that C2 was readily
bioconverted into C1 when fed to M. echinospora ΔBN::gmrA,
which lacks the entire gentamicin gene cluster except the re-
sistance gene gmrA. It appeared therefore that the enzyme cat-
alyzing the terminal 6′-N-methylation step must be encoded by a
gene outside the limits of the known cluster. Also, cell-free lysate
ofM. echinospora ΔBN was shown to carry out this conversion in
the presence of SAM, and the enzymatic activity proved stable to
initial fractionation using selective ammonium sulfate pre-
cipitation. We therefore contemplated searching for the elusive
terminal methyltransferase by two parallel routes, one by conven-
tional enzyme purification from M. echinospora and the other by
bioinformatic analysis of genome sequence followed by the cloning
and testing of plausible candidates. In the end, the genome-assisted
approach proved quicker.
The whole-genome sequence ofM. echinosporaATCC15835 was
determined and assembled as described in Materials and Methods.
To identify candidate genes for the methylation at 6′-N of C1a
and C2, we chose the protein sequences of two authentic
aminoglycoside N-methyltransferases as probes. One of these was
IstU, which is proposed to catalyze an analogous 6′-N-methylation
step during biosynthesis of istamycin in Streptomyces tenjimar-
iensis (12, 16). Four candidate genes—orf0086, orf1678, orf12159,
and orf3626 (GenBank accession nos. MF036116, MF036117,
MF036132, and MF036133) with 40, 36, 38, and 27% protein
sequence identities, respectively, to IstU (SI Appendix, Table
S4)—were chosen, and each was inactivated in M. echinospora
ATCC15835 through in-frame deletion. However, none of these
mutants was found to abolish the methylation at 6′-N.
The second probe sequence chosen was GenN. In total, 19
candidate genes (GenBank accession nos. MF036118–MF036131
and MF036134–MF036138) were identified using the BLASTP
program (28), with percentage sequence identities to GenN rang-
ing from 26.67 to 40.35% (SI Appendix, Table S4). Each candidate
gene was cloned into expression vector pET28a(+) in Escherichia
coli, and cell extracts were assayed for their ability to catalyze
SAM-dependent conversion of C2 into C1, monitored by LC-ESI-
HRMS (SI Appendix, Fig. S6A). The results showed that only
the cell-free lysate of BL21(DE3)/pET28a(+)-genL(orf5365) trans-
formed C2 to C1. No other candidate, including boiled BL21(DE3)/
pET28a(+)-genL, catalyzed this conversion. The cell-free lysate of
BL21(DE3)/pET28a(+)-genL also catalyzed the conversion of C1a
to C2b significantly (SI Appendix, Fig. S6B). These results strongly
suggested that this enzyme, named GenL, is the elusive terminal
methyltransferase catalyzing methylation on 6′-N of C1a and C2. The
genL (GenBank accession no. MF036122) is separated from the
known gentamicin biosynthetic cluster by 2.54 Mbp.
To confirm the function of genL, the gene was removed through
in-frame deletion from the genome ofM. echinosporaATCC15835.
This mutant was verified through Southern blotting (SI Appendix,
Fig. S4 A and B) and then fermented, followed by LC-ESI-HRMS
analysis of the extract. The results showed selective loss of the
C1 and C2b components of the gentamicin C complex (Fig. 1 and
SI Appendix, Fig. S4C), confirming that genL is the unique and
essential gene catalyzing 6′-N-methylation on C2 and C1a in gen-
tamicin biosynthesis. Complementation in trans with the wild-type
genL gene (SI Appendix, Fig. S5E) substantially restored C1 pro-
duction (60% of wild type) and gave C2b levels 240% of wild type
(SI Appendix, Fig. S4C).
GenL Is Highly Specific for Terminal 6′-N-Methylation of C1a and C2.
Recombinant GenL was expressed as an N-terminally His6-tagged
protein and purified from E. coli BLR cells as described inMaterials
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Fig. 3. Production of gentamicin intermediates in feeding experiments.
Extracted ion chromatograms are shown from LC-ESI-HRMS of feeding ex-
periments: (A) ΔBN::gmrA+genD1 fed with 2, 3, 7, and 9, respectively.
(B) ΔBN::gmrA+genK fed with 2, 3, and 4, respectively. (C) ΔBN::gmrA+genN
fed with 2 and 7, respectively. Host refers to ΔBN::gmrA.
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Fig. 4. LC-ESI-MS analysis of in vitro activities of GenN on gentamicin in-
termediates 2 and 7. In the presence of SAM, GenN catalyzed methylation of
(A) 2 to 3 and (B) 7 to 9, respectively. The extracted ion traces of substrates
are in gray and those of the products are in black.
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and Methods. After affinity purification on a Co2+-NTA column and
gel-filtration chromatography on Sephadex S200, GenL was essen-
tially homogenous as judged by SDS/PAGE and eluted as a single
peak of protein with an estimated Mr of 43,000, roughly consistent
with its being a dimer in solution (calculated Mr of the subunit
29,000). This purified enzyme preparation was active in the
conversion of both C2 to C1 and of C1a to C2b (Fig. 5 A and B),
as monitored by HPLC-MS, but was inactive against C2a, the
C-6′ epimer of C2 (Fig. 5C).
Kinetic analysis of the SAM-dependent methyltransferase activity
of GenL was carried out with either C2 or C1a as substrate, using a
continuous colorimetric assay based on enzymatically coupling the
production of S-adenosylhomocysteine (SAH) to a change in ab-
sorbance at 510 nm (29, 30). The data were fitted to the integrated
form of the Michaelis–Menten equation. For C2, kcat was 0.043·s
−1,
and Km was 77.8 ± 8 μM; while for C1a, kcat was 0.040·s−1, and Km
was 346.8 ± 86 μM (Fig. 5 D and E). The same assay was also used
to screen several other pathway intermediates (C2a, G418, JI-20A,
and JI-20B) (20), and other gentamicin-related aminoglycosides,
including sisomicin, kanamycin A, kanamycin B, and tobramycin.
All of these were found to be essentially inactive as substrates for
GenL, except for a slow reaction with sisomicin.
Discussion
Methylation is an important reaction in the biosynthesis of spe-
cialized metabolites in both plants and microorganisms, where it
contributes significantly to the chemical diversity of the products
(31, 32). The results presented here significantly advance our un-
derstanding of the way in which methylation shapes the branched
biosynthetic pathway to the gentamicin C complex, an established
drug used to combat serious infections. These insights are key to
the success of efforts to redirect the course of biosynthesis toward
specific components of the complex and give an appreciation
of the scope for altering the methylation pattern on the gen-
tamicin pseudotrisaccharide scaffold to generate various me-
tabolites for testing as antibiotics or for other therapeutic
indications (3). Methyltransferases involved in the biosynthesis
of natural products have considerable potential for the engi-
neering of new derivatives (33–35). There is renewed interest in
aminoglycoside antibiotics (3, 36) driven in part by the increasing
incidence of pathogenic strains resistant to many other antibiotics
but also by encouraging evidence that toxicity and vulnerability to
resistance mechanisms can be ameliorated by semisynthesis (37).
For example, etimicin is prepared from gentamicin C1a (38) and
plazomicin (currently in phase III trials) from the gentamicin-like
sisomicin (39). If the single components of the gentamicin C com-
plex can be efficiently prepared by low-cost direct fermentation, it
will widen the scope for such efforts.
In previous work, three consecutive methylation steps in
the later stages of gentamicin biosynthesis have been firmly
established as being catalyzed, respectively, by the 3′′-N-methyl-
transferase GenN, the 4″-C-methyltransferase GenD1, and the 6′-C-
methyltransferase GenK (19, 20, 28). However, here we have shown
that the three methylations may take place in an alternative
order, giving rise to a form of network. A commercial batch of
gentamicin C has been shown to contain as trace contaminants
gentamicins lacking one or more of these methyl groups (27), and
specific deletion of genN has been shown, for example, to increase
the yield of several 3′′-N-desmethylgentamicins (19, 28). To ex-
plore this further, we therefore constructed the complete combi-
natorial set of seven mutants in which one, two, or all three of
methyltransferase genes had been independently deleted in-frame.
LC-ESI-HRMS analysis of these mutants gave indications of the
substrate flexibility of these enzymes.
First, the ΔgenD1ΔgenKΔgenN mutant produced no inter-
mediate more advanced than 2, which confirms that no other
methyltransferase present in M. echinospora can methylate this
molecule. Also as expected, in ΔgenD1ΔgenK, ΔgenNΔgenK,
and ΔgenD1ΔgenN, 3, 6, and 7, respectively, were seen. In the
ΔGenK mutant, GenN clearly out-competes GenD1 because the
products are those of the normal pathway: 3 and 4. In the ΔgenD1
mutant, GenK and GenN collaborate to produce doubly methyl-
ated 9 via either 3 or 7, while in the ΔgenN mutant, GenK and
GenD1 collaborate to produce doubly labeled 10 via either 6 or 7.
Purification of the intermediates accumulated in these mu-
tants also provided a panel of gentamicin metabolites. Further
insight into methyltransferase substrate specificity was gained by
feeding these individual metabolites to strains of M. echinospora
stripped of the resident gentamicin biosynthetic gene cluster,
except for a resistance gene and genN, genD1, or genK. The re-
sults showed that GenK and GenD1 are somewhat more versa-
tile than GenN in accepting alternative substrates (Fig. 3). Even
so, 6 is not a substrate for either GenK or GenN, so 10 must be
formed via 7, and since 10 is not a substrate for GenN, neither 6
nor 10 are competent intermediates in biosynthesis of the gen-
tamicin C complex. Thus, the only minor alternative pathways
that can contribute to production of the gentamicin C complex
lead from 3 to 9 to 5, inverting the normal order in which
GenD1 and GenK act, or from 2 to 7 to 9 to 5, if GenK acts
before GenN and GenD1 (Fig. 1). Agar diffusion assays against
Bacillus pumilis showed that, with the important exception of the
natural intermediate X2, derivatives tested that lacked any of the
core methylations of the gentamicin C complex were essentially
inactive (SI Appendix, Fig. S7), emphasizing the importance of
both the pattern and the extent of this modification for antibiotic
activity. The relatively tight selectivity of the three methyltransferases
rationalizes why the conventional pathway dominates in the wild
type. Although these results provide proof of concept for directing
biosynthesis toward gentamicin-related metabolites with altered
methylation patterns, enzyme engineering to modify substrate
specificity would be required to make this an efficient process,
and further modification of those templates would be required to
restore antibiotic activity.
The biosynthetic genes for all aminoglycoside antibiotics so
far studied are found clustered together on the genome, and
this has greatly facilitated their analysis (13, 17). A surprising
feature of the gentamicin biosynthesis in M. echinospora is that
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Fig. 5. In vitro methyltransfer activities of GenL. In the presence of SAM,
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the methyltransferase gene genL, which we have shown here is es-
sential to catalyze the terminal methylations, is located 2.54 Mbp
away from the known biosynthetic gene cluster. This was previously
annotated as an orphan methyltransferase, along with many other
similar genes in M. echinospora, and it is not located near any
recognizable genes of specialized metabolism. The dependence of a
biosynthetic gene cluster on the collaboration of a remotely located
gene is not unprecedented (40), and its discovery here demonstrates
the power of a genome-driven approach to uncover such “missing”
elements of a biosynthetic pathway. Whether GenL also catalyzes
a different reaction in primary or specialized metabolism is un-
known. We have characterized recombinant GenL as a homodi-
meric SAM-dependent enzyme with exactly the expected substrate
specificity. GenL showed no activity against earlier intermediates
in the pathway. GenL bears very limited sequence similarity to the
3′′-N-methyltransferase GenN, and it would be of considerable
interest to compare the crystal structures, substrate ranges, and
reaction mechanisms of these two enzymes.
The separation of gentamicin C components has previously been
at least partially achieved by chemical derivatization, column
chromatography, and deprotection (8). The present work shows
the feasibility, with the identity and role of every methyltransferase
established, of achieving the same goal more conveniently by di-
rect fermentation of an appropriately engineered mutant strain.
Given the growing global threat of antibiotic resistance, it is of
pressing importance to maximize the potential of the existing ar-
senal of antibacterial compounds, as well as to seek new targets.
The results that we have obtained should encourage the use of
individual congeners as starting points for semisynthesis to create
novel aminoglycosides, Also, the reportedly lower toxicity of cer-
tain components of the gentamicin C complex (6, 7) deserves to be
fully and critically evaluated, and the present work brings this
prospect closer.
Materials and Methods
Methods describing gene cloning, gene deletion and complementation,
fermentation of strains and feeding experiments, LC-ESI-HRMS analyses,
isolation and characterization of compounds, genome sequencing, cell-
free assay, protein overexpression and purification, enzymatic assay, and
kinetic characterization are described in detail in SI Appendix, SI Materials
and Methods.
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